Once the medication is stopped, weight regain is common unless lifestyle changes are made
Groundbreaking research reveals that per- and polyfluoroalkyl substances (PFAS) can seep through human skin and enter the bloodstream
McGraw-Hill / Lange rxlist.com (Onglyza ) Keywords Linagliptin Trade Name: Tragenta Drug Class: oral hypoglycemics Mechanism of Action: An inhibitor of dipeptidyl peptidase-4 (DPP-4), a protease that degrades the incretin GLP-1 Pharmacokinetics: biliary tract excretion - unique elimination route amongst the DPP-4 inhibitors useful for Type II diabetic patients with reduced renal function
[1] [3] Key risk factors for developing hypotension on GLP-1 therapy include: Concurrent use of antihypertensive medications, especially diuretics, ACE inhibitors, or ARBs Concomitant use of SGLT2 inhibitors, which can cause osmotic diuresis and volume depletion Baseline blood pressure in the low-normal range (systolic 90-110 mmHg) Advanced age (65 years and older) Autonomic dysfunction or diabetic neuropathy Rapid or substantial weight loss Inadequate fluid intake or gastrointestinal side effects causing dehydration Concomitant use of other medications that lower blood pressure Patients with type 1 diabetes using off-label GLP-1 therapy or those with longstanding type 2 diabetes and cardiovascular autonomic neuropathy may be at higher risk for orthostatic hypotension
Beyond type 2 diabetes, GLP-1 drugs might also benefit patients with type 1 diabetes
Kelly Mosher, board-eligible obstetrician and gynecologist, explains the science behind use of these medications
;Resize=(606,341))
